A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

NCT07253285 on ClinicalTrials.gov · last registry update 2026-09-30

Recruiting now, toward 460 participants. Due to report 20 March 2030, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Relative change in body mass index (BMI). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 460
Started: 2026-01-08
Primary completion: 2030-03-20 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Relative change in body mass index (BMI)

Conditions studied

Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.